The size of the global immunoprecipitation market is predicted to grow at a CAGR of 6.24% from 2023 to 2028 and be worth USD 999.72 million by 2028 from USD 738.65 million in 2023.
The growing opportunities for funding and investments in next-generation DNA sequencing and increasing R&D activities in the genomics field by governmental and non-governmental organizations drive the global immunoprecipitation market growth. Immunoprecipitation approaches have seen considerable technological advancements. Advances in chromatin immunoprecipitation technology have resulted in Chromatrap Immunoprecipitation (ChIP) technology, a bead-free way of doing chromatin immunoprecipitation. The market is predicted to rise rapidly due to epigenetic advances made opportunities by ChIP-seq. In addition, the immunoprecipitation testing market is expected to grow due to the growing incidence of autoimmune disorders, which necessitates antibody-antigen interaction testing.
Collaborations between researchers and organizations have significantly aided the growth of the life science sector. Academic advancements in cellular and gene therapies have resulted in novel strategies for biological therapeutics. The scope of new findings is broadening due to increasing research efforts in genomics, immunotherapy, and microbiome. With advanced genetic tools, R&D for genomics for illness research, medication development, and tailored therapy design has grown steadily. In addition, many regulatory and federal agencies are launching strategic attempts to make genetic research more accessible.
The growing awareness regarding the benefits of early disease detection and diagnosis fuels the use of immunoprecipitation techniques for biomarker identification and detection of disease-specific antibodies and the rising adoption of precision medicine supports the immunoprecipitation market growth. The growing use of antibody therapeutics for the treatment of various diseases, including cancer and autoimmune disorders, increasing focus on protein-protein interactions, rising investments for the R&D of proteomics, growing use of mass spectrometry for protein identification and characterization and increasing need for high-throughput techniques for large-scale protein analysis and screening further boost the growth rate of the immunoprecipitation market.
Lack of standardized protocols and variability in immunoprecipitation techniques, the complexity of immunoprecipitation techniques and the availability of alternative techniques for protein analysis and characterization, such as Western blotting, ELISA, and mass spectrometry hinder the market growth. The time-consuming nature of the immunoprecipitation technique, limited commercial availability of high-quality antibodies, regulatory hurdles, poor awareness and education about the benefits and applications of immunoprecipitation techniques among researchers and clinicians and compatibility issues of immunoprecipitation techniques with downstream applications, such as mass spectrometry or protein analysis platforms further limits the market’s growth rate.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Covered |
By Product, Type, End-User, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Key Market Players |
Merck KGaA, Thermo Fisher Scientific, Abcam, Bio-Rad Laboratories, Abbkine Scientific Co. Ltd., Cell Signaling Technology, Rockland Immunochemicals, BioLegend, Takara Bio, GenScript Biotech Corporation, and Geno Technology |
Due to the widespread usage of various antibodies, beads, and buffers, the reagents segment dominated the global immunoprecipitation market in 2023. The growing use of reagents by researchers to customize their immunoprecipitation workflows by selecting specific reagents based on their requirements is one of the key factors driving segmental growth. The availability of a diverse range of immunoprecipitation reagents such as antibodies targeting different proteins, agarose beads with varied functionalities and optimized buffers and flexibility and customizability of reagents further boost the segmental growth.
On the other hand, the kits segment is predicted to grow at a promising CAGR throughout the forecast period due to the availability of a diverse product portfolio. The benefits of kits such as the convenience, time-saving benefits and standardized protocols primarily propel the segmental growth. The growing adoption of kits by academic and research institutions considering their ease of use, consistent results, and reduced training requirements further fuel the segment’s growth rate. The growing investments in proteomics research contribute to segmental growth.
The individual protein segment had the leading share of the global market in 2023 and is predicted to continue the segmental domination throughout the forecast period. The rising emphasis on protein-protein interactions research and increasing emphasis on developing new therapies and personalized medicine promote segmental growth.
On the other hand, the tagged protein segment is expected to grow at a promising CAGR during the forecast period. The growing use of tagged protein in recombinant protein expression systems for purification and detection and the significance of tagged protein in protein localization and interaction studies within cells primarily support segmental growth.
The academic and research institutes segment held the major share of the global market in 2023 and is predicted to grow at a healthy CAGR during the forecast period. The growing emphasis on proteomics and genomics research by academic and research institutes majorly drives segmental growth. The availability of financial resources, funding and grants by the governmental organizations to support the R&D efforts of academic and research institutes further fuel the segment’s growth rate.
The CROs segment is predicted to grow at the highest CAGR during the forecast period. The growing trend of outsourcing research activities by the pharmaceutical, biotechnology and academic institutions, cost-effective solutions and scalability in conducting research studies by CROs boost the segmental growth.
Geographically, the North American region had the largest share of the global market in 2023 and the regional domination is anticipated to continue throughout the forecast period. The availability of well-established pharmaceutical and biotechnology industries that drive demand for immunoprecipitation techniques in drug discovery and development is one of the major factors propelling the North American immunoprecipitation market. The strong presence of academic and research institutes conducting cutting-edge proteomics and genomics research and the availability of significant research funding and grants to support advancements in immunoprecipitation technology contribute to the growth of the North American market. The U.S. accounted for the major share of the North American market in 2023 and is expected to grow at a prominent CAGR during the forecast period. The rising emphasis on precision medicine and personalized healthcare, increasing demand for biomarker discovery and validation using immunoprecipitation, technological advancements and adoption of automated platforms for high-throughput immunoprecipitation analysis and growing focus on understanding protein-protein interactions for therapeutic target identification and validation in the U.S. further fuel the growth rate of the U.S. market.
The APAC immunoprecipitation market is another biggest regional segment in the worldwide immunoprecipitation market and is predicted to grow at the highest CAGR during the forecast period. Rapidly growing biotechnology and pharmaceutical industries are driving the demand for immunoprecipitation techniques in drug discovery and development in the Asia-Pacific region and propelling the APAC market growth. The growing investments for the R&D of proteomics and genomics using immunoprecipitation by academic and research institutions, the large patient population and the rising prevalence of chronic diseases promote the immunoprecipitation market growth in the Asia-Pacific region. China held the major share of the APAC market in 2022 and the same is predicted to continue during the forecast period. Technological advancements in healthcare infrastructure, rising adoption of advanced protein analysis techniques like immunoprecipitation, emphasis on precision medicine and personalized healthcare approaches, an increasing number of initiatives and funding support by the Chinese government for research and development in life sciences, including proteomics research and immunoprecipitation technology drive the Chinese market growth.
Europe's immunoprecipitation market captured a considerable share of the global market in 2023 and is predicted to showcase a noteworthy CAGR during the forecast period. The growing number of research collaborations among academic institutions and biopharmaceutical companies that drive the innovation and adoption of immunoprecipitation techniques in Europe majorly support the market growth. The presence of well-established healthcare infrastructure supporting biomarker discovery and clinical proteomics research, growing investment in proteomics research and personalized medicine initiatives and strong regulatory frameworks promoting the adoption of advanced analytical techniques such as including immunoprecipitation in drug development further boost the European market growth. The United Kingdom, Germany and France collectively captured around 60% of the European market share in 2023 and the same pattern is predicted to continue throughout the forecast period. The rising emphasis on understanding epigenetic regulation and chromatin biology and the growing focus on studying post-transcriptional regulation and RNA-protein interactions favors the immunoprecipitation market in these countries.
Latin America is a noteworthy regional market for immunoprecipitation worldwide and is predicted to grow at a healthy CAGR during the forecast period. The growing investments in healthcare infrastructure and research institutions, increasing focus on understanding disease mechanisms and biomarker discovery for improved healthcare outcomes and the presence of biopharmaceutical companies and contract research organizations (CROs) offering immunoprecipitation services propel the Latin American market growth. Brazil accounted for the major share of the Latin American market in 2023.
MEA is predicted to witness steady growth during the forecast period. The growing initiatives and funding support by the governments of MEA countries for life sciences research, including proteomics and collaborative research efforts with international partners drive the regional market growth. Saudi Arabia held the major share of the MEA market in 2023.
Companies playing a promising role in the global immunoprecipitation market profiled in this report are Merck KGaA, Thermo Fisher Scientific, Abcam, Bio-Rad Laboratories, Abbkine Scientific Co. Ltd., Cell Signaling Technology, Rockland Immunochemicals, BioLegend, Takara Bio, GenScript Biotech Corporation, and Geno Technology.
By Product
By Type
By End-User
By Region
Frequently Asked Questions
The global immunoprecipitation market size is estimated to value USD 999.72 million by 2029.
Based on the product, the reagents segment is anticipated to lead the global immunoprecipitation market from 2024 to 2029.
The North American regional market dominated the immunoprecipitation market in 2023.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region